Crestor approved for reduction of cardiovascular risk

The Korea Food and Drug Administration has recently approved Crestor (rosuvastatin calcium)) tablets of AstraZeneca to reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD).

An increased risk of CVD is based on age (≥50 years for me...